Croda International H1 2026 Results Highlight Consumer Care Growth and Transformation Savings

Consumer Care Segment Drives Growth with Strong Beauty Actives Performance

Croda's Consumer Care division posted the strongest H1 performance, achieving 8% organic sales growth, well above the Group’s 4.6% overall increase. Beauty Actives led with 19% growth, while Beauty Care rose 4%, Home Care 9%, and Fragrances & Flavours 8%. This growth reflects successful portfolio revitalisation targeting both premium and affordable beauty markets, capturing market share amid consumer financial pressures. Management highlighted that global beauty brands increasingly focus on science-backed efficacy and innovation to compete with challenger brands, benefiting Croda’s specialised ingredient portfolio.

Q2 2026 saw particularly strong momentum in Consumer Care, with 14% organic sales growth driven by a 27% surge in Beauty Actives, up from 3.6% in Q1. The company’s direct-to-customer sales model and R&D realignment towards customer co-creation and new ingredient development are key drivers. For example, Croda repositioned a plumping ingredient to address "drooping face" effects linked to rapid weight loss from GLP1 drugs, showcasing adaptability to emerging consumer health trends. Adjusted operating profit in Consumer Care increased 14.3% organically to A398.1m, benefiting from higher volumes and improved pricing and mix.

Life Sciences Segment Steady Despite Pharma Solutions Challenges

The Life Sciences division reported flat organic sales in H1 2026. Pharma sales grew 1% organically, supported by a 7% increase in Pharma Ingredients, which account for over 70% of Pharma sales. This growth aligns with Croda’s strategy to focus on excipients for drug delivery and consumer health ingredients, supported by relaunches of key topical and animal health ingredients previously deprioritised during the pandemic.

However, Pharma Solutions, focused on vaccine adjuvants and lipid technologies, declined 17% due to project revenue phasing into H2 2026. Crop Protection sales fell 2% following strong prior-year restocking, partially offset by a 4% rise in Seed sales. Adjusted operating profit in Life Sciences dropped 2.4% organically to A353.7m, reflecting headwinds in solutions and crop protection offsetting pharma ingredient gains. Management expects Pharma Solutions project revenues to improve in H2, supported by a solid order book.

Industrial Specialties Segment Contracts Amid Market Pressures

Industrial Specialties experienced a 2% organic sales decline in H1 2026, with adjusted operating profit falling 19.8% organically to A34.0m. Representing about 11% of Group sales at A399.5m, the segment faced a 3.6% volume decrease partially offset by 1.7% positive pricing and mix. The decline is attributed to a tough prior-year comparator and challenging industrial market conditions. Profitability pressures were more pronounced than sales declines, though specific margin drivers were not detailed.

As the smallest division, Industrial Specialties appears to be managed for cash generation and selective investment rather than aggressive growth, with strategic focus on Consumer Care and Life Sciences. Investors should monitor this segment for potential impacts from industrial market softness or portfolio restructuring.

New and Protected Products Outperform with 6.9% Organic Growth

New and Protected Products (NPP), representing recently launched or IP-protected ingredients, grew 6.9% organically in H1 2026, surpassing total Group organic sales growth of 4.6%. This metric highlights Croda’s innovation-driven growth strategy, with Beauty Actives and Pharma Ingredients as primary contributors. The company expanded its biotechnology capabilities via a new UK biotech centre of excellence, complementing existing facilities in France, Italy, Canada, Korea, and the UK. Emphasis on customer co-creation and biotech innovation supports expectations that NPP will continue to outpace overall sales growth, driving profit growth beyond volume increases.

Transformation Programme Achieves A318m Savings in H1 2026

Croda’s transformation programme delivered A318m incremental savings in H1 2026, adding to A310m in H1 2025 and A318m in H2 2025, totaling approximately A346m towards the A3100m annualised efficiency target by 2028. Additionally, A350m in working capital improvements are anticipated by that year. These efficiencies contributed to an operating margin increase from 17.2% in H1 2025 to 17.7% in H1 2026 despite modest sales growth.

The programme includes cost reductions, supply chain optimisation, procurement initiatives, and structural changes such as Pharma business reorganisation and R&D realignment. Management indicated the business is "already well invested," signaling future capital expenditure will be selective, enabling margin improvements without significant incremental investment. The current trajectory supports achieving the A3100m efficiency goal by 2028.

Asian Manufacturing Expansion Completed with New Facilities in India and China

Croda finalized its Asian manufacturing expansion with new production sites in Dahej, Gujarat, India, and Guangzhou, China. The Indian greenfield facility offers lower carbon emissions and cost per unit compared to existing sites. The Guangzhou facility combines Fragrances and Beauty Actives production, serving a growing customer base in the region. These investments align with Croda’s strategy to position manufacturing close to fast-growing Asian markets.

This expansion supports the commercial success of ceramide ingredients acquired in 2023, which saw 44% sales growth in H1 2026 following enhanced performance verification. With capex focused on Asian manufacturing and Pharma capabilities in the UK and USA completed, management plans highly selective future capital expenditure, marking the end of peak investment and prioritising returns.

Free Cash Flow Up 36.8% on Capital Discipline

Free cash flow rose 36.8% to A338.3m in H1 2026 versus A328.0m in H1 2025, reflecting operational improvements and disciplined capital spending as the Group transitions from heavy investment to optimisation. Leverage improved slightly to 1.4x from 1.5x, while the interim dividend was maintained at 48.0p per share to rebuild earnings coverage.

Adjusted EBITDA increased 5.5% to A3207.9m, representing 23.6% of sales, up from 23.2% in the prior year. The company targets A350m in working capital improvements by 2028 to further boost free cash flow. Holding the dividend steady reflects a balanced approach to shareholder returns and financial strength.

Limited Impact from Middle East Geopolitical Tensions

Despite Middle East tensions, Croda’s H1 2026 results showed minimal disruption. Price increases offset input cost inflation, and limited pre-buying in Consumer Care balanced lower Fragrances & Flavours sales in the region. Strong geographic and product diversification helped maintain stability. Q2 2026 organic sales grew 9%, with Consumer Care up 14%, indicating robust demand despite geopolitical uncertainty. However, management remains cautious about potential second-half risks.

Full-Year 2026 Guidance Maintained Amid Uncertainty

Croda reaffirmed its full-year 2026 guidance, expecting Group organic sales growth within the 3-6% range and further adjusted operating margin expansion driven by Consumer Care and Life Sciences profitability and transformation benefits. H1 organic sales growth of 4.6% and 6.7% profit growth align with these targets. An update on Q3 sales is scheduled for 5 November 2026. Currency fluctuations, particularly USD and EUR exposure, pose potential risks, with estimated A34m negative impact on full-year operating profit if rates remain at June 2026 levels.

Financial Framework to 2028 Focuses on Stronger Returns

Croda’s strategic plan through 2028 targets consistent sales growth, improved profitability, sustainable cash flow, and enhanced returns on invested capital (ROIC). H1 results demonstrate progress with 4.6% organic sales growth, 6.7% profit growth, 36.8% free cash flow increase, and margin expansion to 17.7%. The company’s selective capex approach and successful ceramide commercialisation support confidence in delivering improved ROIC and shareholder value without major new investments.